CROSSJECT publie ses résultats du premier semestre 2026 et présente une structure financière profondément renforcée

Crossject reported a H1 2026 net loss of €8.6M, widening from €4.9M a year earlier, as operating revenue fell 40% to €4.8M and BARDA billings declined to €2.5M from €6.6M. Its May €15M capital increase materially improved liquidity to €12.3M from €5.1M at year-end, restored equity to €3.0M from negative €4.9M, and reduced adjusted net financial debt to €7.8M from €17.4M. Post-close, BARDA extended the ZEPIZURE development contract through June 2030 and added $4.7M of non-dilutive funding, bringing total program funding to $48.0M, though regulatory approval timing remains undisclosed.

Analysis

ALCJ’s balance-sheet repair reduces near-term insolvency risk but does not establish a self-funded path to commercialization. At the current underlying operating-cost run-rate, available cash appears to cover roughly 6-9 months absent BARDA reimbursements, working-capital movements, debt service and further capex; the key valuation variable is therefore the timing and cash conversion of regulatory and procurement milestones, not the reported improvement in net debt. The absence of auditor limited review increases the required discount for a micro-cap issuer whose equity base remains thin relative to liabilities.

The non-dilutive BARDA extension improves strategic credibility and can support milestone-related cash inflows over 1-3 years, but it also concentrates execution risk in one US government counterparty and an authorization process outside management’s disclosed timetable. Manufacturing qualification and inventory build introduce a second-order risk: fixed industrial costs and working capital can rise before any procurement revenue is recognized, creating another financing need even if the regulatory path remains intact.

The equity overhang is material. Full exercise of the outstanding warrants would add roughly 8.1m shares, or about 13% versus the June share count, at €2.68; a sustained move toward that level may attract warrant-arbitrage selling rather than signal fundamental rerating. Consensus may over-credit the cash increase while underestimating that it was principally externally financed and that recurring development losses remain substantial. BNP has no meaningful direct earnings sensitivity; its relevance is limited to research/distribution visibility through its Portzamparc affiliate.

Key Decisions for Investors

• No core long in ALCJ before independently verifiable regulatory timing or a funded procurement/first-delivery commitment. Treat the name as an event-driven watchlist, not a fundamentals compounder, over the next 1-3 months.
• For high-risk biotech capital only, initiate a small ALCJ long after confirmation that cash runway extends beyond 12 months without a new equity raise; target a 2-3x upside on authorization/procurement de-risking, with a hard exit on any financing announcement below the warrant exercise price or a material regulatory delay.
• Monitor quarterly cash burn, supplier payables, inventory growth and capitalized development spend. A sequential acceleration in cash consumption without matching BARDA collections would falsify the balance-sheet-repair thesis and should trigger avoidance or exit.
• Use any rally toward €2.68 as a risk-management point rather than automatic momentum confirmation: warrant dilution and potential hedging supply become relevant above that level. Reassess only if trading volume and disclosed institutional ownership demonstrate capacity to absorb the incremental shares.